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Abstract Targeting the activation function-1 (AF-1) domain located in the N-terminus of
the androgen receptor (AR) is an attractive therapeutic alternative to the current
approaches to inhibit AR action in prostate cancer (PCa). Here we show that the AR AF-1
is bound by the cochaperone Bag-1L. Mutations in the AR interaction domain or loss of
Bag-1L abrogate AR signaling and reduce PCa growth. Clinically, Bag-1L protein levels
increase with progression to castration-resistant PCa (CRPC) and high levels of Bag-1L in
primary PCa associate with a reduced clinical benefit from abiraterone when these tumors
progress. Intriguingly, residues in Bag-1L important for its interaction with the AR AF-1 are
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within a potentially druggable pocket, implicating Bag-1L as a potential therapeutic target
in PCa.
DOI: https://doi.org/10.7554/eLife.27159.001
Introduction
The androgen receptor (AR) plays a central role in the development of prostate cancer (PCa). Cur-
rent approaches aimed at reducing persistent AR signaling either inhibit the production of andro-
gens, or compete with endogenous ligands for binding to the AR C-terminal ligand-binding domain
(LBD) (Helsen et al., 2014). While these therapies are initially effective in the advanced disease set-
ting, PCa will eventually progress to a lethal, therapy-resistant state termed castration-resistant PCa
(CRPC). In most cases of CRPC, AR continues to play a dominant role. Newer androgen synthesis
inhibitors such as abiraterone and AR antagonists such as enzalutamide have been developed as sec-
ond-generation therapies for the treatment of CRPC (de Bono et al., 2011; Scher et al., 2012;
Beer et al., 2014). Nevertheless, while initially effective in the treatment of CRPC, most cases will
develop resistance to these therapies (Mostaghel et al., 2014). One of the major drawbacks of
these drugs is that they target the AR LBD (either directly or indirectly). Although the AR LBD is
often regarded as the major site of AR regulation, most of the AR transactivation function is con-
trolled through its N-terminal activation function 1 domain (AF1), which is subdivided into the tau-1
(amino acids 100–359) and tau-5 regions (amino acids 360–528) (Claessens et al., 2008). Further-
more, multiple AR variants expressed in CRPC completely lack a LBD (Guo et al., 2009), illustrating
the need for alternative modes of AR inhibition. Targeting the AR AF-1 therapeutically has been
challenging, due to its intrinsically disordered nature and lack of enzymatic activity or rigid binding
clefts (Lavery and McEwan, 2008). However the lack of secondary or tertiary structure of intrinsi-
cally disordered regions (IDRs) of proteins, such as those found in the AR AF-1 domain, could be an
advantage in providing a large surface area for protein-protein interactions (Wright and Dyson,
2009). IDRs can fold upon binding to their targets, allowing them to undergo conformational
changes and participate in protein complex formations (Dyson and Wright, 2005). Although these
interactions tend to be more transient and of lower affinity than complex formation between struc-
tured protein regions (Latysheva et al., 2015), they have become exceedingly important for control-
ling the function of IDR-containing proteins. Proteins that bind the unstructured AR AF-1 domain
may constitute regulatory targets for inhibiting AR action.
Bag-1 (Bcl-2-associated athanogene-1) is a multifunctional protein involved in a number of key
cellular processes including proliferation, differentiation, cell cycle, transcription and apoptosis
(Townsend et al., 2003a). Its main function is as a cochaperone and nucleotide exchange factor for
Hsp70/Hsc70 (Alberti et al., 2003). Four Bag-1 isoforms (Bag-1L,  1M,  1 and  1S) exist in humans
and are generated from the same mRNA by a leaky scanning mechanism (Takayama et al., 1998;
Yang et al., 1998). Although the Bag-1 family members differ in their N-terminal domains, their
C-terminal (BAG) domains are conserved and essential for interaction with Hsp70/Hsc70
(Brehmer et al., 2001; Sondermann et al., 2001). Bag-1L, the largest family member, is the only
one that possesses a nuclear localization sequence and is therefore localized in the nucleus
(Takayama et al., 1998) where it enhances the transactivation function of several nuclear hormone
receptors, including the AR (Froesch et al., 1998; Knee et al., 2001; Shatkina et al., 2003;
Jehle et al., 2014). The function of Bag-1L on AR action is mediated through the direct interaction
between two regions of each protein. We have recently shown that Bag-1L uses a N-terminal dupli-
cated GARRPR motif to bind to a pocket near the AR LBD, termed binding function-3 (BF-3)
(Jehle et al., 2014). Additionally, Bag-1L binds via its C-terminal BAG domain to the AR N-terminal
domain (NTD) (Shatkina et al., 2003). However, details of this interaction and its consequences are
unknown.
Here we show that the conserved BAG domain within the C-terminus of Bag-1L selectively inter-
acts with the intrinsically disordered, but partially folded N-terminal AR tau-5 domain. Disrupting
this interaction by knocking out or mutating the BAG domain of Bag-1L alters the structural proper-
ties of the AR NTD and receptor folding, and reduces the ability of AR to bind to chromatin and reg-
ulate transcription.
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Results
Bag-1L is important for AR activity and function in PCa
Bag-1L has been reported to upregulate the activity of AR (Froesch et al., 1998; Knee et al., 2001;
Shatkina et al., 2003). However, previous studies have not been able to clearly separate the func-
tion of Bag-1L from that of the other Bag-1 family members (Krajewska et al., 2006; Ma¨ki et al.,
2007). To specifically determine the function of Bag-1L, we employed a transcription activator-like
effector nuclease (TALEN) approach that targets the first codon (CTG) of Bag-1L (Figure 1A), result-
ing in the complete knock-out (KO) of this protein. We used this approach in hormone-dependent
LNCaP cells where we observed, concomitant with the loss of Bag-1L, an upregulation of the other
Bag-1 isoforms (i.e. Bag-1S and Bag-1; Figure 1B); this is consistent with the translation of the Bag-1
mRNA by a leaky scanning mechanism. No alterations of AR levels were observed in response to
Bag-1L KO, even in the presence of dihydrotestosterone (DHT). We also created rescue cell lines, re-
expressing either an empty vector construct or (wild-type) Bag-1L (Figure 1C), to exclude potential
off-target effects. Cell growth, over a 5 day period, was determined for all cell lines (Figure 1D).
While loss of Bag-1L significantly reduced PCa growth, re-expression of Bag-1L (but not that of the
empty vector) could reverse this phenotype, confirming that LNCaP cell growth is Bag-1L
dependent.
Since LNCaP cell growth is primarily driven by AR activity, we next tested whether Bag-1L has any
effect on the AR cistrome or transcriptome. We performed ChIP-seq in hormone-depleted control,
Bag-1L KO and the rescue LNCaP cell lines, treated for 4 hr with vehicle (ETOH) or 10 nM DHT. We
observed only limited binding of AR in response to vehicle treatment, regardless of the presence or
absence of Bag-1L (Figure 1—figure supplement 1). This is in concordance with previously pub-
lished AR cistromes (Wang et al., 2007). As previously reported (Wang et al., 2009), AR binding
increased in response to DHT in the control cells (Figure 1E). In comparison, increase in AR binding
eLife digest Prostate cancer is the second most common cancer in men around the world. The
cancer relies on a protein called the androgen receptor in order to develop and grow. Currently,
some of the most common treatments for prostate cancer, especially in its advanced stages, are
drugs that block the activity of this receptor. However, such treatments are only successful for a
limited period of time, and so alternative methods to inhibit this receptor are still needed.
The androgen receptor must bind to a number of proteins to carry out its activity. These proteins
include one called Bag-1L, which is also important for the development of prostate cancer. Stopping
such a protein from binding with the androgen receptor might represent a new way to treat
prostate cancer; but first it will be important to understand how this interaction actually regulates
the activity of the receptor.
Now, Cato et al. have analyzed samples of cancer cells that had been collected from 43 patients
with prostate cancer and found that Bag-1L levels increase as the disease progresses. Looking at the
patients’ medical records then revealed that therapies targeting the androgen receptor were less
effective in people with high levels of Bag-1L. Conversely, altering, removing or inhibiting Bag-1L in
prostate cancer cells grown in the laboratory made the receptor less active and made the cells grow
slower.
Further experiments went on to reveal that Bag-1L interacts with a regulatory region of the
androgen receptor. Cato et al. note that this region remains largely unexplored therapeutically,
because it has some unique structural properties that restrict how much it can interact with drug
molecules. Targeting Bag-1L and stopping it from binding to this region of the androgen receptor
would represent a different approach to inhibiting the androgen receptor and treating patients with
prostate cancer. Together these new findings should provide pharmaceutical companies with much
of the information they would require to immediately start screening for therapies that target Bag-
1L. Ultimately, Cato et al. hope that any follow-up findings will benefit prostate cancer patients by
improving the currently available treatments.
DOI: https://doi.org/10.7554/eLife.27159.002
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Figure 1. Loss of Bag-1L inhibits PCa cell growth and reduces the AR cistrome and transcriptome. (A) Schematic of the TALEN approach to knockout
Bag-1L expression. The TALEN target sequences are highlighted in grey and the start codon (CTG) of Bag-1L is highlighted in yellow. Note, the start
codons for the other Bag-1 isoforms remain intact. The resulting coding sequence, which is missing the Bag-1L start codon and flanking regions, is
shown in red. (B) Western blot of nuclear extracts from hormone-deprived control (Ctr) and Bag-1L KO (KO) cells treated with vehicle (ETOH) or 10 nM
DHT for 4 hr. Protein levels of Bag-1 isoforms (Bag-1L,  1S and  1, but not  1M) and AR are shown. The expression of the nuclear protein Lamin B1
was used for equal protein loading. (C) Western blot of Bag-1L and AR levels in control, Bag-1L KO and Bag-1L KO rescue cell lines, as indicated. b-
actin was probed to ensure equal protein loading. (D) Proliferation assay of indicated cell lines grown in complete media and counting on days 0 and 5.
Data are the averages of three independent experiments ± SEM, normalized to day 0. p-values were calculated using standard t test; *p0.05;
Figure 1 continued on next page
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was modest in the Bag-1L KO cells, and peaks were overall weaker than those observed in the con-
trol cells (Figure 1F). This implies that Bag-1L is necessary for effective AR binding to chromatin.
Concomitantly, Bag-1L re-expression, but not the re-expression of the empty vector construct, could
restore the AR binding sites (Figure 1F). The difference in AR binding in the presence and absence
of Bag-1L was independent of the duration of DHT treatment, as confirmed by directed qPCR at
three AR-bound enhancers (Figure 1—figure supplement 2).
To test if the reduction in AR binding in response to Bag-1L loss has any repercussions on the AR-
dependent transcriptome, we next performed RNA-seq in hormone-deprived control and Bag-1L
KO cells, treated for 16 hr with ETOH or 10 nM DHT. RNA- and ChIP-seq data were correlated using
GenomicRanges (Bioconductor) and direct AR target genes were defined as genes with DHT-
induced differential expression (p(FDR)0.05, fold change 1.5) that harbor a DHT-responsive AR
binding site within 50 kb of their transcription start site (TSS). Using this approach, we determined
599 direct AR target genes in the control and 306 in the Bag-1L KO cells (Figure 1—source data 1).
Using the HALLMARK function from GSEA we established that most of those genes lost in response
to Bag-1L KO are associated with ‘androgen response’ (p=3.3910 31; q = 1.710 29) (Figure 1—
figure supplement 3), supporting our hypothesis that one of the functions of Bag-1L in PCa is to
regulate AR transactivation.
One of the consequences of the loss of a chaperone or cochaperone is an alteration of the folding
properties of its client proteins (Balchin et al., 2016; Mayer and Bukau, 2005). The impaired chro-
matin binding and transactivation function of the AR in cells lacking the cochaperone Bag-1L may
therefore arise from an inability of the AR to adopt the appropriate conformation for its function. To
test this, we employed fluorescence resonance energy transfer (FRET) using AR with its N- and C-ter-
mini tagged with CFP and YFP, respectively. This allowed us to measure the intra- and inter-molecu-
lar AR N/C-terminal interactions associated with the transactivation of the receptor (Schaufele et al.,
2005). Experiments were carried out in hormone-depleted control and Bag-1L KO cells treated with
vehicle (ETOH) or 10 nM DHT for 2 hr, and FRET signals were quantified (Figure 1G). We observed
a much attenuated (and overall lower) FRET response to DHT in the Bag-1L KO compared to the
control cells (i.e., mean difference of 0.24 ± 0.01 in the control versus mean difference of 0.09 ± 0.01
in the KO cells). Taken together, these results suggest that there are significant alterations in the
inter-domain interaction and folding of the AR in the absence of Bag-1L that effect the ability of the
receptor to efficiently respond to DHT, bind to chromatin and regulate gene expression.
The BAG domain of Bag-1L binds the tau-5 region of AR
We have previously shown that Bag-1L enhances AR transactivation via direct interaction of the two
proteins (Jehle et al., 2014). We demonstrated that a novel GARRPR motif, found at the N-terminus
Figure 1 continued
***p0.001; ****p0.0001. (E) Venn diagram of AR cistromes from replicate ChIP-seq experiments in hormone-depleted control (red) and Bag-1L KO
(blue) cells treated for 4 hr with DHT. The union of binding sites is indicated. (F) Signal profiles and heatmaps of AR ChIP-seq data (centered on the AR
peaks) from indicated cell lines. Signals are shown for sites with an AR peak in one or more cell lines. Cells were starved of hormone and treated with
10 nM DHT for 4 hr prior to the experiment. (G) Top, fluorescence images of CFP-AR-YFP-expressing hormone-depleted control or Bag-1L KO cells,
treated with ETOH or 10 nM DHT for 2 hr. The FRET channel, which is corrected by 17% of ICFP, is shown in red, the raw CFP in blue, and the YFP,
under direct excitation at 488 nm, in yellow. Results are from two independent experiments with more than 10 images. Scale bar: 10 mm. A schematic
representation of the CFP-AR-YFP construct is shown below. Bottom, Quantification of CFP-AR-YPF FRET. IFRET/(IFRET +IDonor) ratios in the nucleus are
shown. Data is the result of readings from more than 25 cells per sample and is presented as mean ±SD. ****p0.0001.
DOI: https://doi.org/10.7554/eLife.27159.003
The following source data and figure supplements are available for figure 1:
Source data 1. Direct AR-target genes in TALEN control compared with Bag-1L KO cell lines.
DOI: https://doi.org/10.7554/eLife.27159.007
Figure supplement 1. Signal profiles and heatmaps of AR ChIP-seq data in Bag-1L control, KO and rescue cell lines in the presence of vehicle.
DOI: https://doi.org/10.7554/eLife.27159.004
Figure supplement 2. ChIP qPCR validation of three AR enhancer sites in Bag-1L control and KO cells.
DOI: https://doi.org/10.7554/eLife.27159.005
Figure supplement 3. Top five HALLMARK terms (GSEA) associated with direct AR-target genes lost in Bag-1L KO compared to control cells.
DOI: https://doi.org/10.7554/eLife.27159.006
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of Bag-1L, interacts with the BF-3 pocket of the AR LBD. We further noted that the C-terminus of
Bag-1L binds the AR NTD (Shatkina et al., 2003; Jehle et al., 2014). To demonstrate that these
interactions contribute to AR action, we next performed a series of mammalian one-hybrid assays
involving full-length Bag-1L and different domains of AR. Bag-1L enhances the activity of the previ-
ously identified AR LBD (in a hormone-dependent manner) as well as the AR AF-1 domain
(Figure 2A). Moreover, Bag-1L enhances AR activity via the tau-5 domain within the AR AF-1
(Shatkina et al., 2003) (Figure 2B), a region known for its hormone-independent receptor activity
(Jenster et al., 1995). We have previously shown that the interaction of AR tau-5 is with the Bag-1L
BAG domain, or its flanking regions (Shatkina et al., 2003). To specifically delineate which residues,
or combinations of residues are involved in this interaction, we employed a SPOT-synthesis tech-
nique that allows the screening of a large number of synthetic peptides (Frank, 2002). We synthe-
sized short overlapping peptides (21 amino acids each) spanning the entire C-terminal domain of
Bag-1L onto a cellulose membrane and incubated it with bacterially-purified GST-tagged AR tau-5.
Once specific binding was established by immunoblotting, alanine substitutions were introduced
into the synthesis of positively identified spots, until single amino acids were identified in the BAG
domain that destroy the interaction with AR tau-5 (Figure 2—figure supplement 1). A triple muta-
tion of K231/232/279A, referred to as CMut hereafter, was able to significantly decrease the interac-
tion of AR and Bag-1L in a GST pull-down (Figure 2C) and co-IP experiment (Figure 2D), and
reduce the AR NTD activity in a mammalian one-hybrid assay (Figure 2E). Additionally, Bag-1L
CMut significantly altered the AR N/C-interaction compared to wild-type Bag-1L (Figure 2F), similar
to what we observed in the FRET experiments in response to DHT treatment in the Bag-1L KO cells
(Figure 1G). CMut Bag-1L- compared to wild-type Bag-1L-expressing cells additionally displayed a
reduction in AR chromatin binding by ChIP-seq (Figure 2—figure supplement 2), similar to that
described for the total loss of Bag-1L (Figure 1F), and a corresponding reduction in hormone-
dependent AR function (Figure 2—figure supplement 3). Moreover, we could show that several
evolutionarily conserved residues within the BAG domain of Bag-1L (primarily in helices 2 and 3),
when mutated, impair the ability of Bag-1L to enhance AR AF-1 transactivation to a similar extent as
the CMut Bag-1L protein (Figure 2—figure supplement 4). This indicates that mutating the BAG
domain disrupts the Bag-1L:AR response similar to what we observed for the complete loss of Bag-
1L.
To test if mutations in the BAG domain would disrupt the integrity of associated biochemical
complexes, we next employed quantitative, stable isotope labeling with amino acids in cell culture
(SILAC) combined with rapid immunoprecipitation mass spectrometry of endogenous proteins
(RIME) (Mohammed et al., 2013) of LNCaP cells that stably express FLAG-HA-tagged wild-type or
CMut Bag-1L. Association of AR, but not Hsp70 (HSPA1), was disrupted in Bag-1L biochemical com-
plexes in the context of the triple mutation (Figure 2G); these data agree with the results of our
GST pull-down (Figure 2C) and co-IP experiments (Figure 2D). Several proteins which exhibited
decreased association with CMut Bag-1L (Figure 2—source data 1) are annotated with functional
roles in protein synthesis, localization, or other aspects of proteostasis (Powers and Balch, 2013;
Taipale et al., 2014; Labbadia and Morimoto, 2015) (Figure 2—source data 2). The dynamics we
observed in the biochemical complex as a function of the Bag1L mutant is consistent with our
hypothesis that Bag-1L is involved in the folding of AR (Figures 1G and 2F), suggesting a broader
role for the BAG domain in proteome homeostasis.
The reduction of interactors for the mutant Bag-1L could, in principle, be the result of an altered
BAG domain conformation brought about by the triple mutation. To test this, we recorded 13C cor-
relation nuclear magnetic resonance (NMR) spectra to compare Ca and Cb shifts (Sattler et al.,
1999), which are predominantly influenced by the secondary structure of a protein. Comparison of
the Ca and Cbshifts revealed no significant changes in the wild-type and mutant BAG domain pep-
tide (Figure 2—figure supplement 5), suggesting that the extent of a-helix formation is essentially
unchanged for the two proteins. However, about one third of residues that make the three antiparal-
lel, helix bundles of the wild-type BAG domain (Briknarova´ et al., 2001) shifted to new positions or
demonstrated reduced signal intensities in 1H15N-HSQC NMR spectra in response to the K231/232/
279A mutations (Figure 2—figure supplement 6). This is most likely due to a destabilization of the
entire protein caused by the three mutations, a consequence of which is a significant change in the
3D-structure of Bag-1L and hence an altered interactome of CMut compared to wild-type Bag-1L
(Figure 2G).
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Figure 2. The Bag-1L:AR interaction is mediated by K231/232/279 in the BAG domain of Bag-1L. (A, B) Mammalian one-hybrid assay in HeLa cells
transfected with indicated AR domains linked to Gal4 DBD, subjected to increasing concentration of Bag-1L. The results are the mean of three
independent experiments ± SEM, relative to the empty Bag-1L expression vector. Schematic representations of the AR domains are shown below. AF-1:
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Figure 2 continued on next page
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The Bag-1L:AR interaction alters the structure of the AR NTD and is
druggable
Differences in the structural consequences of the wild-type or mutant BAG domain interaction with
the AR AF-1 was next tested using solution NMR spectroscopy. Addition of the wild-type BAG pep-
tide resulted in the reduction of resonance intensities within the C-terminal part of AR AF-1, indicat-
ing that these two molecules interact transiently (Figure 3A). The residues of AF-1 most affected by
this interaction corresponded to tau-5 and were previously identified as partially folded by NMR
(De Mol et al., 2016), suggesting that the wild-type BAG domain interacts preferentially with this
sub-domain. Moderate decreases in intensity were also observed in tau-1, in the region centered
around residue 275, which has the propensity to adopt extended conformations. This suggests that
although Bag-1L through its BAG domain binds tau-5, the interaction propagates to tau-1. Equiva-
lent experiments carried out with the BAG domain mutant showed a much-attenuated effect, indi-
cating that the strength of the interaction was diminished by the mutations, which agrees with our
previous results (Figure 2).
Given the importance of the Bag-1L BAG domain for the interaction with AR, as well as its signifi-
cance for AR function and activity, it is conceivable that inhibition of the Bag-1L:AR interaction
through this domain might provide a powerful tool to suppress AR transactivation and PCa growth.
We therefore employed the canSAR drug discovery platform (Bulusu et al., 2014; Tym et al., 2016)
to query whether the BAG domain of Bag-1L contains any druggable or ligandable cavities that may
be utilized for drug discovery. We analyzed 44 3D structural snapshots of the BAG domain of human
Bag-1/Bag-1L (Figure 3—source data 1). Although all 44 structures lack a classical ‘druggable’ site
(defined as sites that harbor geometric and physiochemical properties consistent with binding orally-
bioavailable small molecules with strict drug-like properties) (Tym et al., 2016), we were able to
Figure 2 continued
harboring point mutations (as indicated) in their BAG domain and lysates from LNCaP cells. Shown below is a schematic structure of Bag-1L with the
triple mutations in the BAG domain, which abolish the interaction with the AR (but have no effect on Hsp70 binding). NLS: Nuclear localization
sequence; UBQ: Ubiquitin-like domain; BAG: BAG domain. (D) Co-immunoprecipitation of Bag-1L and AR in LNCaP cells stably overexpressing FLAG-,
HA-tagged wild-type (WT) or BAG domain mutant Bag-1L (CMut). The IP was performed using an anti-HA-tag antibody against Bag-1L and an antibody
against AR and Hsp70 to evaluate binding of these proteins to Bag-1L. Equal protein loading was confirmed by probing for expression of Bag-1L, AR,
Hsp70 and b-actin.. (E) Mammalian one-hybrid assay in HeLa cells transfected with pG5DE4-38 luciferase, TK Renilla luciferase, pM-AR AF-1 and
different Bag-1L constructs harboring a wild-type or mutant BAG domain (as indicated). The results are the mean of three independent
experiments ± SEM, relative to the empty Bag-1L expression vector. (F) Mammalian two-hybrid assay in HeLa cells transfected with Gal4 DBD-AR LBD
and VP16-AR-AF-1 and increasing amounts of wild-type (WT) or K231/232/279A mutant Bag-1L (CMut). The results are the mean of three independent
experiments ± SEM, relative to the control Renilla luciferase. (G) Log-log plot of intensities for proteins detected in forward and reverse SILAC RIME
analyses of Bag-1L WT and CMut cells, targeting BAG-1L (dark blue) or IgG (light blue). Black lines represent median IgG-RIME ratios ± 2 standard
deviations. Bag-1L, Hsp70 (HSPA1) and AR are indicated in yellow and red, respectively.
DOI: https://doi.org/10.7554/eLife.27159.008
The following source data and figure supplements are available for figure 2:
Source data 1. List of Bag-1L interactors altered by the BAG domain mutation (2 standard deviations of Bag-1L/IgG control RIME).
DOI: https://doi.org/10.7554/eLife.27159.015
Source data 2. Associated functions (FuncAssociate) of Bag-1L interactors altered by the BAG domain mutation.
DOI: https://doi.org/10.7554/eLife.27159.016
Figure supplement 1. Schematic of the SPOT synthesis technology.
DOI: https://doi.org/10.7554/eLife.27159.009
Figure supplement 2. Overlap between AR cistromes in wild-type and CMut Bag-1L-expressing LNCaP cells.
DOI: https://doi.org/10.7554/eLife.27159.010
Figure supplement 3. Top ten GO-terms (GSEA) associated with direct AR-target genes lost in the Bag-1L CMut- compared to the wild-type Bag-1L-
expressing cells.
DOI: https://doi.org/10.7554/eLife.27159.011
Figure supplement 4. Conserved BAG domain mutations that inhibit the AR AF-1 transactivation.
DOI: https://doi.org/10.7554/eLife.27159.012
Figure supplement 5. CBCACONH data of wild-type and CMut Bag-1L.
DOI: https://doi.org/10.7554/eLife.27159.013
Figure supplement 6. 15N-HSQC spectra of wild-type and CMut Bag-1L.
DOI: https://doi.org/10.7554/eLife.27159.014
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Figure 3. The BAG domain mutations decrease AR binding and overlap a druggable pocket. (A) Top left: Normalized peak intensities of AR-AF-1
(residues 142–448) in the presence of GST (grey), or the GST-fused wild-type (blue) or K231/232/279A mutant BAG domain (red) of Bag-1L. A schematic
of the tau-1 and tau-5 regions and the nascent secondary structure of these domains are shown. Partially folded helices are indicated by grey cylinders
and regions with the propensity to adopt an extended conformation are indicated by black rectangles. Bottom and right: Close-up HSQC spectra of
Figure 3 continued on next page
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identify a large ‘ligandable’ cavity, which is druggable using peptides or peptidomimetic drugs
(Figure 3B). Moreover, we could demonstrate that the three amino acids (K231/232/279) important
for AR binding lie within (K231 and 232) or just outside the edge (K279) of this cavity (Figure 3C).
This agrees with our independent findings from the pull-down and luciferase assay (Figure 2C and
E), where mutation of residues K231 and K232 jointly, but not K279 alone, reduced the binding to
AR. However, in these experiments the biggest effect was achieved in response to a simultaneous
mutation of all three residues, suggesting that the triple mutant behaves similarly to the complete
loss of Bag-1L. The overlap between these experimental results and the computational prediction of
the cavity suggests that pharmacological interference with the predicted cavity of Bag-1L is highly
likely to impair AR action.
The Bag-1L:AR interaction can be inhibited by the thioflavin Thio-2
To test if pharmacological interference of the BAG domain of Bag-1L would indeed impair AR
action, we tested the efficacy Thio-2, a tool compound BAG domain inhibitor. Thio-2 has previously
been postulated to bind to the BAG domain and to inhibit the interaction between Hsp70 and Bag-
1 (Enthammer et al., 2013; Papadakis et al., 2016). A consequence of this is the reduce growth of
breast cancer cells, but so far this compound has not been tested in PCa. Thio-2 was indeed able to
abrogate the endogenous Bag-1L:AR interaction in LNCaP cells (Figure 4A), as well as inhibit the
androgen-dependent LNCaP cell growth (IC50 = 17.5 mM; Figure 4B). Moreover, Thio-2, unlike the
AR N-terminal inhibitors EPI-001 or ido-EPI-002 (Andersen et al., 2010) and the AR LBD inhibitor
enzalutamide, was able to effectively suppress Bag-1L function in a mammalian-1H assay (Figure 4C
and D). This suggests that targeting Bag-1L through inhibition of its BAG domain, is a therapeutic
possibility to abrogate AR function and reduce PCa growth.
Bag-1L promotes androgen-dependent and -independent PCa growth
To test whether mutation in the BAG domain of Bag-1L (i.e. Bag-1L CMut) could indeed function as
a substitute for Bag-1L inhibition or Bag-1L loss, we measured cell growth of Bag-1L KO cells stably
expressing an empty vector control, or the wild-type or CMut Bag-1L (Figure 5A). Equal protein
expression and AR levels were confirmed by western blotting (Figure 5—figure supplement 1).
While re-expression of wild-type Bag-1L was able to rescue the growth inhibition triggered by Bag-
1L KO, re-expression of the vector or Bag-1L CMut failed to do so. Given this result, we postulated
that over-expression of wild-type Bag-1L should therefore cause an increase in PCa cell growth. We
were able to confirm that overexpression of wild-type, but not CMut Bag-1L, results in an increase in
LNCaP growth (Figure 5B), without any obvious alterations in AR levels (Figure 5—figure supple-
ment 2). Similarly, wild-type Bag-1L overexpression also promotes growth in mouse xenograft
experiments, in intact (Figure 5C) and castrated animals (Figure 5D). However, overexpression of
wild-type Bag-1L (Figure 5—figure supplement 3), did not cause an increase in CRPC growth in
LNCaP-abl and LNCaP95 cells (Figure 5E and F), most likely due to endogenously elevated Bag-1L
levels in these cells compared to the parental LNCaP line (Figure 5—figure supplement 4). Overex-
pression of the CMut Bag-1L protein on the other hand, lead to a dominant negative effect on cell
growth (Figure 5E and F), without any obvious alteration in AR level (Figure 5—figure supplement
5). This suggests that intact and functional Bag-1L mediates growth of CRPC cell models and may
be associated with castration resistance and PCa disease progression.
Figure 3 continued
representative residues (as indicated) of AR-AF-1 alone (black) and in the presence of GST (grey), or the GST-fused wild-type (blue) or K231/232/279A
mutant BAG domain (red) of Bag-1L. (B) 3D-model of the BAG domain of Bag-1L shown in blue, with the predicted druggable pocket highlighted in
gold. (C) Rotations of the structure in (B) with the three residues (K231/232/279) within the BAG domain necessary for the interaction with AR indicated
in red.
DOI: https://doi.org/10.7554/eLife.27159.017
The following source data is available for figure 3:
Source data 1. Distinct 3D-snapshots of the BAG domain of Bag1/Bag-1L.
DOI: https://doi.org/10.7554/eLife.27159.018
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Nuclear Bag-1 is upregulated in CRPC and associates with reduced
clinical benefit from abiraterone therapy
Given our hypothesis that Bag-1L is a driver of castration resistance, we next investigated if Bag-1
(and AR) expression levels change with PCa progression. H-scores were determined by immunohis-
tochemistry (IHC) of matched diagnostic (archival) hormone-sensitive PCa (HSPC) and CRPC biopsies
(Figure 6A) of 43 patients. Bag-1 antibody specificity for IHC was confirmed using Bag-1 siRNA in
HeLa cells (Figure 6—figure supplement 1), and antibody depletion in various cell lines (Figure 6—
figure supplement 2) and patient biopsies (Figure 6—figure supplement 3). Specificity of the AR
antibody for IHC was previously described (Welti et al., 2016). Since Bag-1L is the only Bag-1 family
member localized to the nucleus, H-scores were determined separately for the nuclear and
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Figure 4. The thioflavin Thio-2 inhibits AR function and AR-dependent PCa growth. (A) Co-immunoprecipitation of endogenous Bag-1L and AR in
LNCaP cells, treated with or without 5 mM Thio-2 for 16 hr. A Bag-1L-specific antibody was employed for the IP and an antibody against AR was used to
evaluate binding. IgG IP was carried out simultaneously as a negative control. One-tenth of the input samples are shown, to confirm equal protein
loading. (B) LNCaP cells were grown in complete media and treated with indicated concentrations of Thio-2. IC50 values were determined after 72 hr
using direct cell counts. Data are the averages of three independent experiments. (C) Mammalian one-hybrid assay in HeLa cells transfected with
pG5DE4-38 luciferase, TK Renilla luciferase, pM-AR AF-1 and Bag-1L, and (increasing concentrations of) indicated inhibitors. The results are the mean of
four independent experiments ± SEM. p-values were calculated using standard t test; ns: not significant; ***p<0.001. (D) MMTV luciferase promoter
assay in HeLa cells with MMTV luciferase construct, TK Renilla luciferase and ARDLBD (amino acids 1–682). The results are the mean of three
independent experiments ± SEM. Enza: enzalutamide. p-values were calculated using standard t test; ns: not significant; **p0.01.
DOI: https://doi.org/10.7554/eLife.27159.019
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Figure 5. Bag-1L enhances hormone-dependent and -independent PCa cell growth. LNCaP Bag-1L KO (Bag-1L KO (A)) or parental LNCaP cells
(LNCaP (B)) were transfected with an empty retroviral construct (+Vector; black), or expression vectors for wild-type Bag-1L (+WT; red) or the Bag-1L
K231/232/279A mutant (+CMut; blue). Cells were counted on indicated days by trypan blue exclusion. Data is represented as the mean of three
independent experiments ± SEM. p-values were calculated using standard t test; *p0.05; **p0.01; ****p<0.001. (C, D) Cell lines described in (B) were
injected in 10 intact (C) or 9 castrated, athymic nude mice (D) and tumor volumes were measured at the indicated time points after injection. Data are
represented as mean ±SEM per assay point. p-values were calculated using standard t test; *: p0.05; **: p0.01. (E, F) Cell growth of LNCaP-abl (Abl,
(E) or LNCaP95 cells (F) transfected with an empty retroviral construct (+Vector; black), or expression vectors for wild-type Bag-1L (+WT; red) or the
Figure 5 continued on next page
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cytoplasmic compartments. The Mann-Whitney test was used to compare median H-scores by
matched biopsy. While nuclear Bag-1 (i.e. Bag-1L) levels increased significantly (p<0.0001) in the
progression from HSPC to CRPC, there was little change in cytoplasmic Bag-1 expression (p=0.14)
(Figure 6B). In comparison, both nuclear and cytoplasmic AR levels were significantly increased
(p<0.0001) as patients progressed to CRPC (Figure 6C). Although both nuclear Bag-1 and AR
expression increased substantially with PCa progression, expression levels of the two proteins were
not correlated (Spearman rank correlation coefficient; Figure 6—figure supplement 4).
Given our finding that Bag-1L is a key regulator of AR action (Figure 1), we next investigated the
correlation between nuclear Bag-1 levels and clinical benefits from AR targeted therapy. Of the 43
patients with matched HSPC and CRPC biopsies, 38 had been treated with abiraterone in the CRPC
setting. Of these, 9 (23.7%) were negative and 29 (76.3%) positive for nuclear Bag-1 staining in their
primary tumors. There were no significant differences in baseline characteristics of these patient
groups at diagnosis or at initiation of abiraterone therapy, except for patient performance status
(ECOG PS; p=0.05) (Table 1). Moreover, there was no difference in 50% PSA response rate (33.3%
vs 29.6%; p=1.00; data not shown), but nuclear Bag-1 positive (compared with Bag-1 negative)
patients had a shorter median time to PSA progression (2.8 vs 6.6 months; log rank test p=0.02)
(Figure 6D) and radiological progression (4.9 vs 9.8 months; log rank test p=0.05) (Figure 6E), and a
reduced median time on abiraterone treatment (4.9 vs 10.4 months; log rank test p=0.03)
(Figure 6F). Furthermore, these patients had a decreased median overall survival on abiraterone
treatment (15.6 vs 20.9 months), but this was not statistically significant (log rank test p=0.10) (Fig-
ure 6—figure supplement 5). In contrast, nuclear AR levels, which were positive for all 38 patients
at diagnosis, were not associated with time to PSA progression, radiological progression or overall
survival (Table 1—source data 1). As most of the CRPC biopsies in this cohort were obtained after
patients had developed abiraterone resistance (60.5%), neither Bag-1 nor AR expression was predic-
tive of PSA or radiological progression on abiraterone or overall survival (Table 1—source data 2).
Collectively, these results demonstrate that nuclear Bag-1 (i.e. Bag-1L) increases with PCa progres-
sion and is associated with reduced clinical benefit from abiraterone.
Discussion
Bag-1L is a known regulator of AR action implicated in PCa progression, but its mechanism of action
is poorly understood. We show here that Bag-1L is essential for AR transactivation and function, and
PCa growth. This function is mediated through the direct interaction of Bag-1L and the AR. Muta-
tions that disrupt this interaction, inhibition of the Bag-1L:AR interaction or loss of Bag-1L alto-
gether, alter the structural properties of the receptor and result in changes in the AR cistrome and
transcriptome (Figure 7). We show that this leads to reduced growth of hormone-dependent and -
independent PCa cells in culture and tumors in xenograft mouse models.
Human Bag-1L is one of four polypeptides translated from a single mRNA by a leaky scanning
mechanism (Takayama et al., 1998; Yang et al., 1998) and as a result it has been difficult to
Figure 5 continued
Bag-1L K231/232/279A mutant (+CMut; blue). Cells were counted on indicated days by trypan blue exclusion. Data is represented as the mean of three
independent experiments ± SEM. p-values were calculated using standard t test; *p0.05; **p0.01; ****p<0.001.
DOI: https://doi.org/10.7554/eLife.27159.020
The following figure supplements are available for figure 5:
Figure supplement 1. Western blot of Bag-1L KO rescue cell lines.
DOI: https://doi.org/10.7554/eLife.27159.021
Figure supplement 2. Western blot of Bag-1L over-expression cell lines.
DOI: https://doi.org/10.7554/eLife.27159.022
Figure supplement 3. Western blot of wild-type Bag-1L over-expression CRPC lines.
DOI: https://doi.org/10.7554/eLife.27159.023
Figure supplement 4. Western blot comparison of endogenous Bag-1L levels in PCa and CRPC lines.
DOI: https://doi.org/10.7554/eLife.27159.024
Figure supplement 5. Western blot of BAG domain mutant Bag-1L over-expression CRPC lines.
DOI: https://doi.org/10.7554/eLife.27159.025
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Figure 6. Nuclear Bag-1 levels increased from hormone naı¨ve to CRPC status in PCa patients. (A) Representative immunohistochemistry images of AR
and Bag-1 detection in HSPC and CRPC. Scale bars: 20 mm. (B, C) Expression (H-score) of nuclear and cytoplasmic Bag-1 (B) and AR (C) in 43 matched
patient samples at HSPC and CRPC. Median H-score and interquartile range is shown. p-values were calculated using Wilcoxon matched-pair signed
rank test. (D, E) Kaplan-Meier curves of time to PSA (D) or radiological progression (E) on abiraterone treatment, for nuclear Bag-1 positive (red; n = 29)
and negative (grey; n = 9) patients (at HSPC). Hazard ratios (HR) with 95% confidence intervals (95% CI) and p-values for univariate cox survival model
are shown. (F) Time on abiraterone for patients, negative (grey) or positive (red) for Bag-1 staining at HSPC. Median time and interquartile range is
shown. p-value represents the Mann-Whitney test.
DOI: https://doi.org/10.7554/eLife.27159.026
The following figure supplements are available for figure 6:
Figure supplement 1. IHC control in response to Bag-1 knock-down.
DOI: https://doi.org/10.7554/eLife.27159.027
Figure supplement 2. Cell line validation of Bag-1 antibody for IHC.
DOI: https://doi.org/10.7554/eLife.27159.028
Figure supplement 3. Validation of Bag-1 antibody for IHC using patient samples.
DOI: https://doi.org/10.7554/eLife.27159.029
Figure supplement 4. Correlation between nuclear Bag-1 and AR expression in HSPC and CRPC patient samples.
DOI: https://doi.org/10.7554/eLife.27159.030
Figure supplement 5. Kaplan-Meier curve of overall survival on abiraterone treatment.
Figure 6 continued on next page
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demonstrate its function in biological systems, independent of the other Bag-1 proteins. Previous
studies on Bag-1L function have either employed siRNA approaches, which reduced the expression
of all four isoforms, or Bag-1L overexpression systems (Froesch et al., 1998; Guzey et al., 2000;
Cutress et al., 2003; Shatkina et al., 2003; Jehle et al., 2014). In our present work, we have used
genome editing techniques to specifically knock-out endogenous Bag-1L and additionally rescued
the knockout by re-expressing wild-type Bag-1L. Using this approach, we could demonstrate that
Bag-1L is required for the correct and efficient folding, chromatin binding and transcriptional activity
of the AR. Moreover, utilizing mass spectrometry we could show that in addition to binding and reg-
ulating the activity of AR, Bag-1L binds stress response proteins, underscoring its function as a sur-
vival and antiapoptotic protein and regulator of the proteostasis network (Townsend et al., 2003b;
Mosser and Morimoto, 2004).
We have previously reported that Bag-1L binds the AR through a novel GARRPR motif, found at
its N-terminus, and a BF-3 pocket at the AR LBD (Jehle et al., 2014). However, inhibition of this
interaction by mutating the GARRPR motif had only a modest effect on AR chromatin binding, the
AR-mediated transcriptome and PCa cell growth (Jehle et al., 2014 and unpublished data). Thus,
we believe that the Bag-1L GARRPR:AR BF-3 interaction acts as a modulator, rather than a regulator
of AR activity. This agrees with findings that the BF-3 pocket itself acts as an allosteric modulator for
receptor activity (Este´banez-Perpin˜a´ et al., 2007). In addition to the GARRPR:AR BF-3 interaction,
Bag-1L also binds the AR N-terminus via its BAG domain. A triple mutant (K231/232/279; CMut)
within helices 1 and 2 in the Bag-1L BAG domain was sufficient to inhibit the Bag-1L/AR interaction,
in an Hsp70-independent manner. Although other mutations, primarily within helix 3 of the BAG
domain, also inhibited the binding of Bag-1L and AR, these sites additionally interacted with Hsp70/
Hsc70. The region in AR most affected by binding to Bag-1L maps to the partially folded region
within tau-5, which strongly overlaps the region affected by EPI-001 binding (De Mol et al., 2016).
EPI-001 is a recently developed experimental drug that targets the AR NTD (Andersen et al., 2010).
A derivative of this compound (EPI-506) is currently being employed in clinical trials for CRPC
patients resistant to abiraterone and/or enzalutamide (ClinicalTrails.gov Identifier: NCT02606123).
However, EPI-001 and iodo-EPI-002 were not able to suppress Bag-1L function in a mammalian-1H
assay. Given our findings that the BAG domain of Bag-1L binds and regulates AR (tau-5) with high
specificity, targeting the Bag-1L:AR interaction might be an alternative approach for the treatment
of PCa. This notion is supported by our findings pointing to a druggable pocket within the BAG
domain of Bag-1L, which overlaps our triple mutation (CMut). An inhibitor (Thio-2) that targets the
BAG domain was shown to be efficacious in blocking the antiapoptotic action of Bag-1 in breast can-
cer and melanoma cells (Enthammer et al., 2013; Papadakis et al., 2016). In the present study we
show that it is also effective in inhibiting the Bag-1L BAG:AR tau-5 interaction and suppressing PCa
cell growth.
Aberrant expression of Bag-1 has been described in a variety of human malignancies, such as
breast, lung, cervical, colorectal and hepatocellular carcinoma (Zapata et al., 1998; Rorke et al.,
2001; Clemo et al., 2008; Cutress et al., 2003; Ni et al., 2013). Here we show that the nuclear
Bag-1 (i.e. Bag-1L), but not the other Bag-1 isoforms, is upregulated in PCa patients that progress
from HSPC to CRPC. This is in agreement with previous reports that show that nuclear Bag-1 levels
(Krajewska et al., 2006), or Bag-1L specifically (Ma¨ki et al., 2007), correlates with PCa progression.
However, our study is the first to analyze Bag-1 expression in matched HSPC and metastatic CRPC
biopsies, rather than unmatched tissues from untreated or hormone-refractory tumors. We addition-
ally show that nuclear Bag-1 levels at HSPC status associate with a reduced clinical benefit from abir-
aterone. This is in line with previous reports that overexpression of nuclear Bag-1 correlates with
drug resistance (Ni et al., 2013) and that Bag-1 overexpression is commonly observed in drug-resis-
tant cell lines (Ding et al., 2000; Chen et al., 2002; Liu et al., 2009). Our study provides evidence
of an association between Bag-1 levels and treatment response in PCa, highlighting the prognostic
significance of Bag-1 in this disease.
Figure 6 continued
DOI: https://doi.org/10.7554/eLife.27159.031
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Table 1. Clinical characteristics of patients at HSPC biopsy and initiation of abiraterone treatment.
HSPC: hormone sensitive biopsy, CRPC: castration-resistant prostate cancer, ECOG PS: Eastern Cooperative Oncology Group perfor-
mance status, IQR: interquartile range, SD: standard deviation, NA: not available, PSA: prostate specific antigen, n: number, pts:
patients.
Overall
38 pts
Bag-1 negative
9 pts
Bag-1 positive
29pts p-value
At diagnostic
(archival)
HSPC biopsy
Biopsy Gleason score, n (%)
6 2 (5) 0 (0) 2 (7) 0.40†
7 7 (18) 4 (44) 3 (10)
8–10 27 (71) 5 (56) 22 (76)
NA 2 (5) 0 (0) 2 (7)
Metastatic at diagnosis, n (%)
No 17 (45) 2 (22) 15 (52) 0.25§
Yes 14 (37) 4 (44) 10 (34)
NA 7 (18) 3 (33) 4 (14)
Primary therapy, n (%)
Prostatectomy 4 (11) 0 (0) 4 (14) 0.65§
Radiotherapy 13 (34) 3 (33) 10 (34)
Systemic therapy 21 (55) 6 (67) 15 (52)
PSA at diagnosis, mg/L
Median 46.0 61.0 29.0 0.30*
IQR 13.1–105.9 28.8–150.0 10.0–96.6
At initiation of
abiraterone treatment
Age, yr
Median 69.2 69.5 69.0 0.59*
IQR 65.5–73.3 61.6–74.1 66.1–73.3
Sites of metastasis, n (%)
Node only 4 (11) 0 (0) 4 (14) 0.57§
Bone only 28 (74) 7 (78) 21 (72)
Visceral (with/without bone) 6 (16) 2 (22) 4 (14)
ECOG PS, n (%)
0 12 (32) 6 (67) 6 (21) 0.05§
1 24 (63) 3 (33) 21 (72)
2 2 (5) 0 (0) 2 (7)
PSA, mg/L
Median 185.5 222.0 147.0 0.77*
IQR 83.8–445.8 51.2–781.5 88.0–363.0
Hemoglobin, g/L
Mean 118.1 124.4 116.2 0.18‡
SD 16.0 16.3 15.7
Alkaline phosphatase, U/L
Median 131.0 133.0 129.0 0.85*
IQR 69.0–230.5 64.5–250.5 70.0–231.0
Lactate dehydrogenase, U/L
Median 178.0 161.0 192.0 0.08*
IQR 155.5–247.0 149.5–190.0 160.0–287.0
NA 2 0 2
Albumin, g/L
Table 1 continued on next page
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In conclusion, we demonstrate here the importance of Bag-1L for AR activity and function in PCa.
Combined, our data support targeting the BAG-1L BAG domain:AR tau-5 interaction therapeutically
in the treatment of PCa and CRPC.
Materials and methods
Cell line preparation and maintenance
TALEN Bag-1L KO and vector controls were created as described (Cermak et al., 2011). In brief,
the left Bag-1 TALEN (targeting the sequence ‘GGGCGGTCAACAAGT’) was translated into the
RVD code ‘NN NN NN HD NN NN NG HD NI NI HD NI NI NN NG’ and assembled in pZHY500. The
right Bag-1 TALEN arm (targeting the sequence ‘CGGGGGGGCGCGGAGA’), was translated into
the RVD code ‘HD NG HD HD NN HD NN HD HD HD HD HD HD HD NN’ and assembled in
pZHY501. Subsequently, both arms were subcloned into pZHY013 (a kind gift from Daniel Voytas) to
generate a heterodimeric Fok1 nuclease. The plasmids were then subcloned into pDest12.2 using
the Gateway cloning technology (Thermo Fisher Scientific, Waltham, MA) and transiently transfected
into LNCaP cells using Fugene 6 (Promega, Madison, WI). Transfected cells were selected using
G418 for 24 hr (800 mg/ml). Single clones where isolated by serial dilution and screened for Bag-1L
deletion by western blotting. To verify the genomic deletion, part of exon 1 was PCR-amplified and
cloned into pcDNA3.1 V5 His6 (Thermo Fisher Scientific) using the TOPO cloning kit (Thermo Fisher
Scientific), and sequenced using specific primers (Bag1g14fw 5’-GCTGGGAAGTAGTCGGGC-3’;
Bag1g252rev 5’-CTGGTGGGTCGGTCATGC-3’). Stable TALEN rescue cell lines (Bag-1L KO +Vector
control, Bag-1L KO +Bag-1L WT and Bag-1L KO +Bag-1L CMut) and stable wild-type (Flag-HA-
tagged) Bag-1L overexpressing LNCaP cells were created as previously described (Jehle et al.,
2014), using expression plasmid poZN. HeLa cell lines were employed for transient transfection
Table 1 continued
Overall
38 pts
Bag-1 negative
9 pts
Bag-1 positive
29pts p-value
Mean 35.8 37.8 35.2 0.17‡
SD 4.8 2.4 5.2
Previous treatments for CRPC, n (%)
Docetaxel 27 (71) 5 (55) 22 (76) 0.40§
Enzalutamide 2 (5) 0 (0) 2 (7) 1.00§
Cabazitaxel 5 (13) 0 (0) 5 (17) 0.31§
Subsequent treatments for CRPC, n (%)
Docetaxel 8 (21) 4 (44) 4 (14) 0.07§
Enzalutamide 7 (18) 1 (11) 6 (21) 1.00§
Cabazitaxel 15 (39) 5 (55) 10 (34) 0.44§
*Mann-Whitney test
†Chi-square test for trend
‡Unpaired t test
§Fisher’s exact test
DOI: https://doi.org/10.7554/eLife.27159.032
The following source data available for Table 1:
Source data 1. Association of nuclear Bag-1 or AR expression with clinical benefits from abiraterone therapy.
HSPC: hormone sensitive prostate cancer, CRPC: castration-resistant prostate cancer, PSA: prostate specific antigen, HR: hazard ratio, 95% CI: 95% con-
fidence intervals. a Univariate cox survival model.
DOI: https://doi.org/10.7554/eLife.27159.033Source data 2. Clinical characteristics of patients at time of castration-resistant prostate cancer biopsy.
CRPC: castration-resistant prostate cancer, ECOG PS: Eastern Cooperative Oncology Group performance status, IQR: interquartile range, SD: standard
deviation, PSA: prostate specific antigen, n: number, pts: patients. at-test from linear regression model of Nuclear Bag-1 H-score at the time of CRPC
biopsy bWald test from linear regression model of Nuclear Bag-1 H-score at the time of CRPC biopsy
DOI: https://doi.org/10.7554/eLife.27159.034
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using PromoFectin (PromoCell, Heidelberg, Germany) according to the manufacturer’s instructions.
LNCaP-abl and LNCaP95 cells were a kind gift from Zoran Culig (Innsbruck Medical University, Aus-
tria) (Culig et al., 1999) and Stephan Plymate (University of Washington, Seattle, WA) (Hu et al.,
2012), respectively. Unless otherwise stated, all cell lines were obtained from the American Type
Culture Collection and their identities were confirmed by short tandem repeat profiling (BioSynthe-
sis, Lewisville, TX). They were all confirmed to be mycoplasma negative, using the MycoAlert myco-
plasma detection kit (Lonza, Portsmouth, NH). All cell lines and parental LNCaP cells were cultured
in RPMI 1640 medium or DMEM (for HeLa cells only) supplemented with 10% FBS, penicillin (100 u/
ml), streptomycin (100 u/ml) and L-glutamine (2 mM). For experiments requiring hormone starvation,
cells were grown for 72 hr in phenol red-free RPMI 1640 medium, supplemented with 10% charcoal-
stripped FBS, penicillin (100 u/ml), streptomycin (100 u/ml) and L-glutamine (2 mM). CRPC lines
were continuously cultured under hormone starvation condition as described above. Cell prolifera-
tion experiments were carried out as previously described (Groner et al., 2016).
Animal experiments
All animal experiments were performed per European and German statutory regulations. Animal
protocols were approved by the ‘Regierungspra¨sidium’ Karlsruhe, Germany (AZ 35–9185.81/G-43/
14 ‘Bag-1L-Prostastakarzinomprojekt’). LNCaP xenograft tumor studies were carried out as previ-
ously described for intact (Maddalo et al., 2012) or castrated mice (Eder et al., 2013).
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Figure 7. The Bag-1L is a promising target for the inhibition of the AR NTD. The function of Bag-1L in PCa is to promote the correct folding of the AR,
augment its affinity for chromatin and regulate its transcriptional activity. Loss of Bag-1L, or mutation or inhibition of its BAG domain, leads to the
abrogation of these processes and hence reduction of PCa growth.
DOI: https://doi.org/10.7554/eLife.27159.035
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Patient cohort, human tumor samples and tissue analysis
Patients were identified from a population of men with metastatic CRPC treated at the Royal Mars-
den NHS Foundation Trust. All study participants had given written, informed consent and were
enrolled in institutional protocols approved by a multicenter research ethics committee (Ethics Com-
mittee Centre: London-Chelsea Research Ethics Committee, Reference no. 04/Q0801/60). Forty-
three patients with sufficient formalin-fixed, paraffin embedded (FFPE), matched diagnostic (archival)
HSPC and CRPC tissue were included in our study. HSPC tissue demonstrated adenocarcinoma and
was obtained from either prostate needle biopsy (35), transurethral resection of the prostate (TURP;
3), prostatectomy (4) or bone biopsy (1). CRPC tissue was obtained from the same patients through
biopsies of bone (25), lymph node (10), liver (5), prostate (TURP; 1), bladder (1) or chest wall (1). All
tissue blocks were freshly sectioned and only considered for IHC analyses if adequate material was
present (50 tumor cells). For Bag-1 IHC (using antibody Y166, Abcam), HSPC and CRPC FFPE biop-
sies were first deparafinised, followed by antigen retrieval (microwaving in citrate buffer (pH 6.0) for
18 min at 800 W). The Bag-1 antibody was diluted (1:250) in Dako REAL diluent (Agilent Technolo-
gies, Santa Clara, CA) and tissue was incubated for 1 hr. After washes, the bound antibody was visu-
alized using the Dako REAL EnVision Detection System (Agilent Technologies). Sections were
counterstained with hematoxylin. AR protein expression was determined using the AR mouse mono-
clonal antibody (AR441, Agilent Technologies), as previously described (Welti et al., 2016). Nuclear
and cytoplasmic Bag-1 and AR expression was determined for each case by author D.N.R in a
blinded fashion using the modified H-score (HS) method using formula: [(% of weak staining) x 1] +
[(% of moderate staining) x 2] + [(% of strong staining x 3) to provide a range from 0 to 300
(Detre et al., 1995). HS data was reported as median values with interquartile range (IQR). Demo-
graphic and clinical data for each patient were collected retrospectively from the hospital electronic
patient record system. These characteristics were compared by Bag-1 status at HSPC using Fisher’s
exact test for categorical characteristics, the Chi-squared test for trend for ordinal characteristics
and either an unpaired t-test for continuous data, if normally distributed (e.g. hemoglobin and albu-
min), or a Mann-Whitney test. The characteristics were then compared by Bag-1 HS value at CRPC
biopsy using linear regression models and either a t-test or Walt test. PSA progression was defined
as an increase in the PSA level of 25% or more above the nadir (and by 2 ng/ml); patients who
stopped abiraterone without PSA progression were censored. Radiological progression was defined
as any radiological imaging reporting disease progression; patients who stopped abiraterone with-
out radiological progression were censored. Overall survival was defined as time from initiation of
abiraterone to date of death (35 patients) or last follow up/contact (3 patients).
Protein assays
Co-immunoprecipitation was carried out as described previously (Jehle et al., 2014). Proteins were
isolated using TIVE lysis buffer (50 mM Tris-HCl pH 7.8, 2 mM EDTA, 150 mM NaCl, 1% NP-40, pro-
tease inhibitors), or lysis buffer A (10 mM HEPES pH 7.5, 10 mM KCl, 0.1 mM EGTA, 0.1 mM EDTA,
1 mM DTT, protease inhibitors) plus 0.5% NP-40 and lysis buffer C (20 mM HEPES pH 7.5, 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 25% Glycerol, 1 mM DTT, protease inhibitors) for total, cyto-
plasmic and nuclear proteins respectively. Western blotting was carried out using standard protocols
with following antibodies: Bag-1 (FL-274 and F-7, Santa Cruz Biotechnology, Dallas, TX or Y166,
Abcam, Cambridge, UK), Bag-1L (was obtained from Andrew Cato; Crocoll et al., 2000), AR (N-20,
Santa-Cruz Biotechnology), Hsp70 (K-20, Santa Cruz Biotechnology), Hsp70/Hsc70 (W27, Santa Cruz
Biotechnology), Flag-tag (M2, Sigma Aldrich, St. Louis, MO), HA-tag (F-7, Santa Cruz Biotechnology
or Abcam), b-actin (C4, Santa Cruz Biotechnology or Abcam), vinculin (V9131, Sigma Aldrich), Lamin
B1 (EPR8985, Abcam). Bag-1L and AR inhibitors were produced by Jakob Troppmair (Thio-2), Xavier
Salvatella (EPI-001 and iodo-EPI-002) or purchased from Selleckchem (enzalutamide).
Chromatin immunoprecipitation (ChIP) and ChIP-seq
ChIP was carried out as described (Jehle et al., 2014), using anti-AR antibody (N-20; Santa-Cruz Bio-
technology). Following primers were utilized for directed ChIP qPCR. KLK3 (AREIII) primers were
previously published (Jehle et al., 2014).
TMPRSS2 Fwd: 5’-GCTCACACAGGATCAGAGCA-3’
TMPRSS2 Rev: 5’-TGCTCGTTAGTGGCACATTC-3’
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NKX3.1 Fwd: 5’-TTTGGGCCACCCTGTAAATA-3’
NKX3.1 Rev: 5’-GGGTGGGAGGAGATGAAAAT-3’
ChIP-seq libraries were generated using the ThruPLEX DNA-seq kit (Rubicon Genomics, Ann
Arbor, MI) and were sequenced on the Illumina NextSeq 500 platform at the Molecular Biology Core
Facility (Dana-Farber Cancer Institute). ChIP-seq data was processed using ChiLin2 (Qin et al.,
2016). All ChIP-seq data have been deposited at the GEO depository under accession number
GSE89939.
RNA-sequencing
Total RNA was extracted from cells using innuPREP RNA Mini (Analytic Jena AG, Jena, Germany),
following the manufacturer’s instruction. mRNA libraries were generated using the Illumina TruSeq
stranded mRNA sample kit and 1 mg of total RNA per sample. Library preparation, sequencing on a
HiSeq1500 Illumina platform, and data analysis were carried out at the NGS facility of the Institute of
Toxicology and Genetics (KIT). Fastq files were processed with CASAVA and mapped against the
human reference genome GRCh37 using TopHat 2.0.11 (Trapnell et al., 2009). Reads were quanti-
fied with HTSeq (Anders et al., 2015), using the reference gene annotation from Ensembl. Differen-
tial expression analysis was performed using DESeq2 (Love et al., 2014). All RNA-seq data have
been deposited at the GEO depository under accession number GSE89939.
FRET
Cells were transiently transfected using Lipofectin (Thermo Fisher Scientific) with plasmid CFP-AR-
YFP (Schaufele et al., 2005), generously provided by Marc Diamond. Images were acquired on an
Andor Revolution XD spinning disk laser scanning microscopy system (BFi OPTiLAS) using two color
channels. CFP was excited at 405 nm (90 mW, 100 ms) and its emission collected through a 447/60
nm bandpass filter (center wavelength/width, AHF). YFP was excited at 488 nm (187 mW, 100 ms)
and observed through a 560/55 nm bandpass filter. A longpass dichroic mirror (DCLP 530, AHF) was
used to separate the emission light. In addition, a notch filter (532/10 nm, center wavelength/width,
AHF) was inserted in front of the dichroic mirror to reduce crosstalk between CFP and YFP. Addi-
tional control experiments were performed to minimize crosstalk and direct excitation of YFP. After
background subtraction, FRET signals were calculated using Icorr. FRET= IFRET – 0.17 ICFP. Nuclear
regions were identified manually based on YFP staining. Acquired images were analyzed using
ImageJ (Abramoff et al., 2004).
SPOT assay
Short overlapping peptides (21 amino acids each) spanning the entire human Bag-1L BAG domain
and its flanking regions were synthesized and spotted in duplicates onto amino-PEG cellulose mem-
branes (Intavis AG Bioanalytical Instruments, Cologne, Germany) using an automated SPOT synthe-
sizer (MultiPep, Intavis AG Bioanalytical Instruments) (Frank, 2002). The membranes were incubated
with bacterially-purified GST-AR-tau-5 (amino acids 360–528). Specific binding was detected using
an anti-GST antibody (Santa Cruz Biotechnologies). Alanine substitutions were introduced into the
synthesis of positively identified peptides using site-directed mutagenesis (Agilent Technologies)
and the hybridization procedure was repeated until single amino acids were identified in the BAG
domain that destroyed the interaction with AR tau-5.
GST pull-down, mammalian one- and two-hybrid assays
GST pull-down was performed as previously described (Jehle et al., 2014). Mammalian one-hybrid
experiments were performed as described (Shatkina et al., 2003), using constructs pG5DE4-38 lucif-
erase (Gal4 reporter gene), TK Renilla luciferase, Gal4 fusion genes (pM-AR-AF-1, pM-t1AR, pM-t
5AR) or MMTV luciferase, TK Renilla luciferase and ARDLBD (amino acids 1–682) with pcDNA3 Bag-
1L (wild-type and mutants). Mammalian two-hybrid assays were performed using constructs
pG5DE4-38 luciferase and TK Renilla luciferase (Jehle et al., 2014), and Gal4DBD-ARLBD and VP16-
AR-AF-1 (provided by Karin Knudsen).
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RIME
SILAC-labeled rapid IP-mass spectrometry of endogenous protein (RIME) was carried out essentially
as previously described (Mohammed et al., 2013). Bag-1L WT and CMut cells were grown in media
supplemented with ‘light’ (L-lysine-2 HCl, L-arginine-HCl) or ‘heavy’ isotope labels (13C6L-lysine HCl,
13C6
15N4L-arginine-HCl) and mixed at a 1:1 ratio (30 million cells per treatment arm) prior to IP. Pro-
teins were immunoprecipitated using 20 mg anti HA-tag (Abcam) or rabbit IgG (Santa Cruz Biotech-
nology) antibody-coupled Dynabeads (Thermo Fisher Scientific). Immunoprecipitated proteins were
digested directly on beads as described (Mohammed et al., 2013). Recovered peptides were acidi-
fied with 10% TFA and subjected to batch mode RP-SCX to desalt peptides and remove traces of
detergent (Adelmant et al., 2011). After trapping on a self-packed pre-column (100 um I.D. packed
with 4 cm POROS 10R2; Applied Biosystems, Foster City, CA), peptides were eluted with an HPLC
gradient (0–35% B in 4 hr) and resolved using a self-packed analytical column with integrated ESI
emitter tip (Ficarro et al., 2009) (30 um I.D. packed with 50 cm Monitor C18, Orochem, with ~1 um
ESI tip, flow rate ~30 nL/min) prior to electrospray (voltage = 3.8 kV). Peptides were analyzed by
nanoflow LC-MS/MS using a NanoAcquity UPLC system (Waters Corporation, Milford, MA) coupled
to an Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific), as previously described
(Ficarro et al., 2009). The mass spectrometer was operated in data-dependent mode such that the
top 15 precursor ions in each MS scan (image current detection, 120K resolution, m/z 300–2000, tar-
get 5e5, max inject time = 500 ms) were subjected to both CID (quadrupole isolation, width 1.6 Da,
first mass = 110, CE = 30%, rapid scan, target = 5e3, max fill time = 50 ms, electron multiplier detec-
tion) and HCD (quadrupole isolation, width 1.6 Da, first mass = 110, CE = 30%, target = 5e4, max fill
time = 50 ms, image current detection with 15K resolution). Mascot was used to search peak lists (.
mgf) generated by multiplierz (Askenazi et al., 2009; Parikh et al., 2009) against a forward-reverse
database of human proteins (NCBI refseq). Search parameters specified SILAC quantitation (K + 8,
R + 10), variable methionine oxidation, and fixed carbamidomethylation of cysteine residues, as well
as a precursor mass tolerance of 10 ppm and product ion mass tolerances of 0.6 Da and 25 mmu for
CID and HCD spectra. After filtering results to 1% FDR, SILAC quantitation was performed using
multiplierz scripts for genes or gene groups represented by at least 2 unique peptides. SILAC data
were then normalized according to Bag-1L expression levels (CMut vs. WT). For protein products
detected in ‘forward’ (WT light, CMut heavy) and ‘reverse’ (WT heavy, CMut light) SILAC experi-
ments, ratios were averaged to provide an aggregate CMut/WT ratio. Search results were each fil-
tered to 1% FDR, combined and further filtered to yield proteins represented by 2 or more unique
peptides. Proteins detected in the Bag-1L RIME experiment were considered background and
excluded from further analysis unless total summed peptide signal intensities were 3 fold higher
than those in the control experiment. Genes or gene groups were considered regulated by the
mutation of Bag-1L if ratios deviated by more than 2 standard deviations from median-normalized
IgG control ratios. Data were plotted using R version 3.2.4.
NMR
The 15N-labeled thrombin protease-cleavable GST-fused BAG domain (wild-type or K231/232/279A
mutant) was cloned into pGEX-6P vector (Addgene, Cambridge, MA) and expressed in E. coli strain
BL21 (DE3), grown in M9 minimal medium supplemented with 0.5 g/l 15NH4Cl. The
15N-BAG
domains were cleaved off by rhinovirus 3C protease (PreScission, GE Healthcare, Marlborough, MA).
To remove residual GST, the protein solution was purified using a glutathione sepharose column and
subjected to size exclusion chromatography (Superdex 200, HiLoad 16/60, GE Healthcare). 15N-
HSQC spectra for wild-type and mutant BAG domains (at approximate 500 mM) and standard triple
resonance backbone experiments (HNCA, HNCACB, CBCA(CO)NH) for peak assignment were
acquired at 23˚ C on a Bruker Avance I 600 spectrometer. The spectrometer was equipped with a
broadband triple resonance probe head with 4 scans per increment and a total of 128 increments in
the indirect dimension. For chemical shift calibration and to compare relative signal intensities, 0.2
mM DSS (2,2 Dimethyl-2-silpentane-5-sulfonic acid) was added. Data were processed with NMRPipe
(Delaglio et al., 1995) and analyzed using NMR VIEW (Johnson, 2004).
Expression, purification and nuclear magnetic resonance assignment of isotopically labeled 15N-
AF-1 has been previously described (De Mol et al., 2016). [1H,15N]-HSQC spectra for AR-AF-1 alone
(at a 25 mM concentration), at a 1:5 molar ratio with GST (as a control) or with unlabeled GST-BAG
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(wild-type or mutant) were acquired at 278K on a Bruker 800 MHz spectrometer. Data was proc-
essed using NMRPipe and NMRDraw, and analyzed using CcpNmr Analysis (Vranken et al., 2005).
Peak intensities were normalized and plotted as a function of residue number.
Computational modeling
The 3D structure of human Bag-1L was analyzed using the structure-based druggability algorithm
(Bulusu et al., 2014) developed as part of the canSAR drug discovery resource (Tym et al., 2016).
In short, the algorithm identifies up to 10 cavities on a 3D-structure and measures ~30 geometric
and physicochemical properties for each of these cavities. Such properties include the volume,
enclosure, depth, and complexity of the cavity, as well as the number of hydrogen-bond donors and
acceptors, polarity distribution and the projected ligand-binding energy of the cavity.
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